EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
- PMID: 28698359
- DOI: 10.1158/1541-7786.MCR-16-0383
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Abstract
Anti-EGFR mAb is reported to induce EGFR internalization in colorectal cancer cells. However, the biological relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the relevance of EGFR downregulation with anti-EGFR mAb to antitumor activity in colorectal cancer cells was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was assessed by flow cytometry, and its growth-inhibitory effects were measured by Trypan blue exclusion, in 10 RAS, BRAF wild-type colorectal cancer cell lines, but there was no significant correlation between EGFR number and its growth-inhibitory effect. However, a significant correlation existed between the percentage decrease in the number of EGFRs after cetuximab treatment and its growth-inhibitory effect in those cell lines. Treatment with TGFα, a ligand for EGFR, induced EGFR internalization in colorectal cancer cells, but most EGFRs subsequently recycled to the cell surface, consistent with previous studies. While cetuximab treatment induced EGFR internalization, most receptors subsequently translocated into the late endosome, leading to lysosomal degradation, as revealed by immunoblotting and double immunofluorescence. Cetuximab-sensitive colorectal cancer cells showed greater EGFR internalization, stronger cell growth inhibition, and more augmented apoptotic signals than nonsensitive cells. IHC for EGFR, performed using an EGFR pharmDx Kit (mouse anti-human EGFR mAb clone 2-18C9), in clinical specimens before and after anti-EGFR mAb therapy in 13 colorectal cancer patients showed a significant correlation between the response to anti-EGFR mAb and decreased staining after therapy.Implications: This report clearly demonstrates that anti-EGFR mAb facilitates internalization and subsequent degradation of EGFRs in lysosomes, which is an important determinant of the efficacy of anti-EGFR mAb treatment for colorectal cancer. Mol Cancer Res; 15(10); 1445-54. ©2017 AACR.
©2017 American Association for Cancer Research.
Similar articles
-
Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.Oncol Rep. 2014 May;31(5):2115-22. doi: 10.3892/or.2014.3077. Epub 2014 Mar 11. Oncol Rep. 2014. PMID: 24626880
-
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016. PLoS One. 2016. PMID: 27314237 Free PMC article.
-
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13. Clin Cancer Res. 2017. PMID: 28611205
-
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Eur J Cancer. 2015. PMID: 25673558 Review.
-
[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7. Magy Onkol. 2008. PMID: 18640895 Review. Hungarian.
Cited by
-
Targeted siRNA Delivery Using Cetuximab-Conjugated Starch for Epidermal Growth Factor Receptor-Driven Head and Neck Squamous Cell Carcinoma.Small Sci. 2025 May 15;5(7):2500073. doi: 10.1002/smsc.202500073. eCollection 2025 Jul. Small Sci. 2025. PMID: 40666030 Free PMC article.
-
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.Int J Mol Sci. 2024 Nov 7;25(22):11954. doi: 10.3390/ijms252211954. Int J Mol Sci. 2024. PMID: 39596025 Free PMC article. Review.
-
Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy.iScience. 2023 Jun 26;26(8):107221. doi: 10.1016/j.isci.2023.107221. eCollection 2023 Aug 18. iScience. 2023. PMID: 37520715 Free PMC article.
-
Bivalent EGFR-Targeting DARPin-MMAE Conjugates.Int J Mol Sci. 2022 Feb 23;23(5):2468. doi: 10.3390/ijms23052468. Int J Mol Sci. 2022. PMID: 35269611 Free PMC article.
-
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer.Cancers (Basel). 2021 Jul 20;13(14):3642. doi: 10.3390/cancers13143642. Cancers (Basel). 2021. PMID: 34298853 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous